BPG is committed to discovery and dissemination of knowledge
Expert Consensus
©The Author(s) 2026.
World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112615
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112615
Table 3 Use of acid suppressants in special populations
Treatment
Indication
Dose/frequency
Risk/conditions
Renal impairment
Ranitidine[19]GERD150 mg ODRisk of toxic reactions: In elderly patients with reduced renal function, in patients with hepatic dysfunction
Famotidine[21]Erosive esophagitis20 mg OD or 40 mg every other dayRisk of CNS adverse reactions and QT prolongation in moderate and severe renal impairment
GU/DU
Vonoprazan[63]Erosive esophagitis10/20 mg ODNot recommended: In severe renal impairment (eGFR < 30 mL/minute), for maintenance of healed erosive esophagitis
H. pylori eradication20 mg BD
Hepatic impairment
Vonoprazan[63]Erosive esophagitis10/20 mg ODNot recommended for H. pylori eradication in moderate to severe hepatic impairment
H. pylori eradication20 mg BD


Write to the Help Desk